Bloomberg Businessweek published a feature article in July 20262 describing the American public as becoming "peptide curious by the day." They were not wrong — Google searches for peptide information hit 10 million per month in the US by January 20261, up from 1.3 million in 2024. The Huberman Lab episode with Dr. Abud Bakri reached 5 million listeners in June 2026. The PCAC just voted to recommend six research peptides for legal compounding a week ago.
If you found this platform because of Bloomberg, Huberman, or a friend who would not stop talking about BPC-157 — you are in exactly the right place. Here is what the article got right, what it missed, and the honest next step.
What Bloomberg got right
The article accurately captured the scale of mainstream interest arriving in this space all at once. The "peptide curious" framing is accurate — millions of people have heard the word without understanding what it means, and are looking for trustworthy information rather than vendor sales pitches.
Bloomberg also accurately described the regulatory complexity — that peptides exist in different legal categories depending on the compound, and that the "research use only" designation does not mean what many vendors imply it means.
The piece correctly noted the enforcement wave — the vendor closures, the FDA warning letters, the pharmaceutical company litigation — as the context that makes quality information more important now than ever.
What the article missed
Bloomberg's framing was necessarily broad — a mainstream business publication covering a complex regulatory landscape for a general audience. A few things worth adding:
The July 2026 PCAC hearing — which concluded the same week as the article's publication — was not covered. Six of seven peptides under review received favorable committee recommendations. That is significant context for anyone evaluating whether the regulatory trajectory is improving or deteriorating. It is improving — slowly, through formal processes, but genuinely moving in a positive direction.
The quality gap between gray market and pharmaceutical-grade compounds was mentioned but underemphasized. Independent testing has documented purity levels of 60-85% at some gray market vendors — meaning the dose on the label may significantly overstate what is actually in the vial. This is not a small footnote — it is the central practical risk for anyone sourcing outside the licensed pharmacy system.
The evidence tier variation within "peptides" as a category is enormous. Ozempic and BPC-157 are both peptides. They have nothing else in common. Treating the category as homogeneous — which general media coverage inevitably does — leaves readers without the framework to evaluate any specific compound.
What to actually do if you are peptide curious
Step 1 — Understand what you are actually researching. Not "peptides" as a category — a specific compound with a specific mechanism and a specific evidence base. Our database covers 47+ compounds with honest, evidence-graded profiles for each one.
Step 2 — Check the legal status of that specific compound. The regulatory landscape varies significantly by compound. Some are FDA approved and available by prescription. Some received favorable PCAC recommendations in July 2026 and are moving toward legal compounding. Some are research-use-only with active enforcement pressure. Knowing which category your compound of interest falls into is non-negotiable before making any decisions.
Step 3 — If you decide to research further, understand sourcing quality. If you access compounds through the gray market, understand how to evaluate a certificate of analysis from a credible independent laboratory. Our COA guide walks through exactly what to look for.
Step 4 — Talk to a physician who understands this space. Dr. Abud Bakri — whose Huberman Lab episode brought many people here — is a board-certified internist specializing in this area. There are now telehealth platforms connecting patients with physicians familiar with peptide therapeutics.
Why this platform exists
ThePeptide.expert was built specifically for the peptide curious moment Bloomberg just described. There was no neutral, evidence-graded, vendor-free resource for people arriving in this space without a research background and without an existing connection to the biohacking community.
We have no products to sell. We have no financial relationship with any compound manufacturer. We rate every compound the same way regardless of how popular it is or who wants to sell it to you.
The peptide curious deserve better information than they can find on vendor sites and forum threads. That is the whole point.
Start with the beginner's guide, browse the database, or ask the Expert's Assistant a specific question. You are in the right place.